Latest Philadelphia chromosome Stories
The US Food and Drug Administration has approved a new drug for the treatment of two rare forms of leukemia, including chronic myeloid leukemia (CML), various media outlets have reported.
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse.
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug called ponatinib in a phase I clinical trial.
A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL).
Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.
- totally perplexed and mixed up.